Serum Neuroglobin and HIF-1α in Acute Ischemic Stroke

Sponsor

Shanghai 6th People's Hospital (Other)

Overall Status

Completed

CT.gov ID

NCT02297984

Collaborator

(none)

Enrollment

Location

Duration (Months)

3.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Neuroglobin has shown rich neuroprotective effects against cerebral ischemia and hypoxia, and therefore has the potential to impact outcomes after acute ischemic stroke. Hypoxia inducible factor (HIF)-1α is neuroprotective in several models of experimental brain injury and is increased in brain after acute cerebral infarction in humans and experimental animals.The investigators sought to examine the changes in serum neuroglobin and HIF-1α concentrations in patients with acute ischemic stroke during the initial 96-h period after stroke and assessed the relation between them and the relation of them to prognosis of such patients with acute ischemic stroke.

Condition or Disease	Intervention/Treatment	Phase
Acute Ischemic Stroke

Study Design

Study Type:

Observational [Patient Registry]

Actual Enrollment :

40 participants

Observational Model:

Case-Only

Time Perspective:

Prospective

Official Title:

Changes of Serum Neuroglobin and HIF-1α Concentrations in Early-phase of Acute Ischemic Stroke

Study Start Date :

Oct 1, 2013

Actual Primary Completion Date :

Sep 1, 2014

Actual Study Completion Date :

Oct 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Acute ischemic stroke Patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study.

Outcome Measures

Primary Outcome Measures

Modified Rankin Scale scores [3 months]
0 = No symptoms; 1 = No significant disability. Able to carry out all usual activities, despite some symptoms; 2 = Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities; 3 = Moderate disability. Requires some help, but able to walk unassisted; 4 = Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted; 5 = Severe disability. Requires constant nursing care and attention, bedridden, incontinent; 6 = Dead.

Secondary Outcome Measures

Glasgow Outcome Scale scores [3 months]
Glasgow Outcome Scale 1 = death; Glasgow Outcome Scale 2 = vegetative state; Glasgow Outcome Scale 3 = severe neurological deficit; Glasgow Outcome Scale 4 = mild neurological deficit and Glasgow Outcome Scale 5 = premorbid level of functioning or completely recovery.

Eligibility Criteria

Criteria

Ages Eligible for Study:

42 Years to 76 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Clinical diagnosis of acute ischemic stroke
Admission within 12 hours

Exclusion Criteria:

Lacunar infarction
Cerebral hemorrhagic infarction
Epilepsy or epileptic persons
History of neurological diseases, myocardial infarction, renal and hepatic abnormalities and metabolic diseases
Contraindications to antiplatelet treatments
Serial blood samples could not be obtained